J. DiMasi
Economics and Econometrics · 2003–2016
A researcher in the Science corpus: 4 papers; trusts 1 researcher and is trusted by 4 researchers here, as inferred from the citation graph.
Subfields
- Economics and Econometrics — 8 citations into it; #12,800 of 23,481 by trust here, #2,587 by citations
Whom J. DiMasi trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts J. DiMasi overall
- Ram Mudambi
- B. Munos
- Yuanqi Du
- Henry G. Grabowski
- T. Swift
- Christian Zeller
- A. Alanis
- Eric J. Kunkel
- A. Seyhan
- Paul Grootendorst
Papers from J. DiMasi's perspective
Ordered by how strongly the researchers J. DiMasi trusts endorse each paper. Same corpus, a different order for every researcher.
- The price of innovation: new estimates of drug development costs.
- Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.
- The druggable genome (Nature reviews. Drug discovery)
- Mutations in PCSK9 cause autosomal dominant hypercholesterolemia (Nature Genetics)
- PCSK9: a convertase that coordinates LDL catabolism Published, JLR Papers in Press, November 19, 2008. (Journal of Lipid Research)
- The Black Swan: The Impact of the Highly Improbable
- Seeing What's Next: Using the Theories of Innovation to Predict Industry Change
- Estimating the cost of new drug development: is it really 802 million dollars?
- How to improve R&D productivity: the pharmaceutical industry's grand challenge
- A Comparison of U.S. and European University-Industry Relations in the Life Sciences
Their papers
- The price of innovation: new estimates of drug development costs. (2003) — 4,275 citations
- The cost of biopharmaceutical R&D: is biotech different? (2007) — 601 citations
- Innovation in the pharmaceutical industry: New estimates of R&D costs. (2016) — 1,418 citations
- Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs (2010) — 832 citations